ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,386.27
-0.45%
Dow Jones
39,806.77
0.00%
Gold vs US Dollar
2,426.88
0.02%
Brent Oil
82.30
-1.47%
Bitcoin
71,333.30
-0.16%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Cocrystal Pharma Inc (COCP)

  7. Cocrystal Pharma Inc (COCP) News

Cocrystal Pharma (COCP)

Cocrystal Pharma Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:COCP
DateTimeSourceHeadlineSymbolCompany
13/05/202413:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
13/05/202413:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:COCPCocrystal Pharma Inc
13/05/202413:00GlobeNewswire Inc.Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsNASDAQ:COCPCocrystal Pharma Inc
07/05/202421:30Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:COCPCocrystal Pharma Inc
01/05/202413:00GlobeNewswire Inc.Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal InfluenzaNASDAQ:COCPCocrystal Pharma Inc
28/03/202412:00GlobeNewswire Inc.Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsNASDAQ:COCPCocrystal Pharma Inc
19/03/202412:00GlobeNewswire Inc.Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza ANASDAQ:COCPCocrystal Pharma Inc
01/03/202421:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
08/01/202413:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
04/01/202421:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
04/01/202413:00GlobeNewswire Inc.Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational CandidatesNASDAQ:COCPCocrystal Pharma Inc
02/01/202414:53Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:COCPCocrystal Pharma Inc
21/12/202322:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
06/12/202313:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
06/12/202313:00GlobeNewswire Inc.Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza ANASDAQ:COCPCocrystal Pharma Inc
04/12/202313:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
29/11/202313:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
29/11/202313:00GlobeNewswire Inc.Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West CoastNASDAQ:COCPCocrystal Pharma Inc
27/11/202313:00GlobeNewswire Inc.Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023NASDAQ:COCPCocrystal Pharma Inc
13/11/202313:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
13/11/202313:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:COCPCocrystal Pharma Inc
13/11/202313:00GlobeNewswire Inc.Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development ProgramsNASDAQ:COCPCocrystal Pharma Inc
09/11/202313:00GlobeNewswire Inc.Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West CoastNASDAQ:COCPCocrystal Pharma Inc
31/10/202312:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
31/10/202312:00GlobeNewswire Inc.Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344NASDAQ:COCPCocrystal Pharma Inc
28/09/202313:00GlobeNewswire Inc.Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and CoronavirusNASDAQ:COCPCocrystal Pharma Inc
05/09/202313:00GlobeNewswire Inc.Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment ConferenceNASDAQ:COCPCocrystal Pharma Inc
16/08/202321:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
14/08/202313:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:COCPCocrystal Pharma Inc
14/08/202313:00GlobeNewswire Inc.Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development ProgramsNASDAQ:COCPCocrystal Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:COCP

Your Recent History

LSE
POS
Plexus
LSE
VAL
Valirx
LSE
TERN
Tern
LSE
VAST
Vast Resources
LSE
PHE
Powerhouse Energy
LSE
SYME
Supply@me Capital
LSE
GKP
Gulf Keystone Petroleum
LSE
SOLG
Solgold
LSE
CHLL
Chill Brands
LSE
GGP
Greatland Gold
LSE
LLOY
Lloyds Banking
LSE
KEFI
Kefi Gold And Copper
LSE
SCE
Surface Transforms
LSE
GOLD
LSE
AAZ
Anglo Asian Mining
LSE
SCLP
Scancell
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved